THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Patent applications |
Patent application number | Title | Published |
20160123973 | MULTIMODAL BIOSENSOR - Multimodal biosensor devices are disclosed. A device may include at least two sensors selected from: (i) a nanomechanical resonator; (ii) plasmonic nanodisk antennae; and (iii) a field effect transistor. The biosensor device is capable of transducing the adsorption of biomolecules onto the biosensor device into optical, electrical and/or mechanical signals. | 05-05-2016 |
20160102130 | WATER SOLUBLE G-PROTEIN COUPLED RECEPTOR - Described herein are recombinant integral membrane proteins having multiple transmembrane domains that have been engineered to be less hydrophobic, through alteration of the amino acid sequence of the native protein, but retain the ability to bind their natural ligand. The decreased hydrophobicity of the described proteins makes them more water soluble than the native protein, which allows the described proteins to be expressed in bacteria in large quantities and isolated in the absence of membranes, all while retaining the ability to interact with known ligands. | 04-14-2016 |
20160096866 | POTENT COMPSTATIN ANALOGS - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. Methods of making and using the compounds are also disclosed. | 04-07-2016 |
20160083478 | Compositions and Methods of Treating Tumors - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 03-24-2016 |
20160051188 | QUANTIFICATION OF IN VIVO METABOLITE - A magnetic resonance pulse sequence technique may acquire a water reference spectrum and two water suppressed metabolite spectra and with frequency selective inversion pulse centered at either single frequency, at multiple frequencies, or in a single acquisition. Subtraction of the inverted from non-inverted water suppressed metabolite spectrum results in single or a combination of specific metabolite peak/peaks alone with a flat baseline for easier quantification. | 02-25-2016 |
20160046999 | METHOD FOR DETECTING MUTATIONS IN SINGLE CELLS OR SINGLE MOLECULES - The invention provides a high efficiency fluorescence in situ hybridization (FISH) method for detecting mutations on individual RNA transcripts, including both exonic and intronic RNA transcripts. In certain embodiments, the method is used to quantify allelic expression at the population and single cell level, and also to distinguish maternal chromosomes from paternal chromosomes in single cells. | 02-18-2016 |
20160046724 | TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR - The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain. | 02-18-2016 |
20160041157 | Method for the site-specific covalent cross-linking of antibodies to surfaces - This invention relates to conjugate antibody, drug and nanoparticle compositions and methods of generating the same. This invention further relates to methods of using same for imaging, diagnosing or treating a disease. | 02-11-2016 |
20160039889 | Mono Or Multivalent Botulinum Neurotoxin Based Vaccine Using The Heavy Chain From Serotypes Of Clostridium Botulinum - Disclosed herein are compositions and methods for treating | 02-11-2016 |
20160038727 | SYSTEM FOR DELIVERY OF GASEOUS IMAGING CONTRAST AGENTS AND METHODS FOR USING SAME - Systems and methods for delivering a gaseous contrast agent to the lungs of a subject. | 02-11-2016 |
20160038584 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided. | 02-11-2016 |
20160038111 | RADIOGRAPHIC CONTRAST AGENTS FOR TEMPORAL SUBTRACTION AND DUAL-ENERGY X-RAY IMAGING - Contrast agents for x-ray imaging including stabilized metal nanoparticles and encapsulated nanoparticles, as well as methods for imaging tissue with these agents, are disclosed. Also disclosed are methods of dual energy x-ray imaging using metal nanoparticle contrast agents or encapsulated metal nanoparticles. | 02-11-2016 |
20160032346 | Sortase-mediated protein purification and ligation - The invention relates to a sortase-mediated protein purification and ligation. Specifically, the invention relates to a technique that links protein expression/purification with conjugation to therapeutic agents, imaging agents, or linkers. | 02-04-2016 |
20160032316 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides - This invention provides purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside, and methods of assessing purity of purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside. | 02-04-2016 |
20160030527 | Compositions and Methods for Treatment of Stroke - The present invention provides compositions and methods for treating stroke. The invention relates to inhibiting the level and/or activity of cell debris after the onset of stroke. In certain embodiments, the invention provides for the catabolism or inhibition of at least one of extracellular RNA, extracellular DNA, and extracellular ATP. | 02-04-2016 |
20160001290 | APPARATUS AND METHODS FOR MAKING VESICLES - A microfluidic device includes a substrate and a microfluidic channel embedded in the substrate. The microfluidic channel includes a plurality of fluid inlets, at least one waste outlet, at least one vesicle outlet, a flow junction joining the at least one vesicle outlet and the at least one waste outlet in fluid communication, the flow junction having a fluid flow path that is orthogonal to the plane of the substrate, and at least one membrane between the at least one vesicle outlet and the at least one waste outlet configured to intercept a portion of the fluid flow path. | 01-07-2016 |
20150376240 | ENHANCED AAV-MEDIATED GENE TRANSFER FOR RETINAL THERAPIES - Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention. | 12-31-2015 |
20150368187 | INHIBITORS OF THE TUMOR NECROSIS FACTOR RECEPTOR COMPLEX - The present invention relates to compounds of formula (I) that are inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions: Formula (I) | 12-24-2015 |
20150364324 | NANOCRYSTAL THIN FILM FABRICATION METHODS AND APPARATUS - Nanocrystal thin film devices and methods for fabricating nanocrystal thin film devices are disclosed. The nanocrystal thin films are diffused with a dopant such as Indium, Potassium, Tin, etc. to reduce surface states. The thin film devices may be exposed to air during a portion of the fabrication. This enables fabrication of nanocrystal-based devices using a wider range of techniques such as photolithography and photolithographic patterning in an air environment. | 12-17-2015 |
20150355173 | HIGH-THROUGHPUT METHODOLOGY FOR IDENTIFYING RNA-PROTEIN INTERACTIONS TRANSCRIPTOME-WIDE - Methods of identifying RNA-protein interaction sites are provided. Systems for identifying RNA-protein interaction sites are provided. Systems for identifying secondary structures are provided. Methods of identifying secondary structures are provided. Methods of identifying RNA-binding proteins are provided. | 12-10-2015 |
20150344693 | HYDRAULIC CRUMB SILICONE AND ORTHOTICS COMPRISING SAME - The invention concerns cushioning compositions comprising (a) at least one of urethane polymer and silicone polymeric putty; and (b) hydraulic silicone crumb; said hydraulic silicone crumb being mixed with component (a). The invention also concerns devices and methods using such compositions. Protective devices have been used to protect the hoofs of animals. Shoes have been used to protect the hoofs from damage while the animal is walking or running. | 12-03-2015 |
20150338436 | WEARABLE SYSTEM FOR ACCELEROMETER-BASED DETECTION AND CLASSIFICATION OF FIREARM USE - A system for detecting and classifying firearm use comprising is provided. The system includes a wearable gunshot detection device and a remote monitoring system. The wearable gunshot detection device is configured to detect an acceleration of an extremity of an individual to which the gunshot detection device is attached, determine acceleration data based on the detected acceleration, and determine whether the acceleration data corresponds to a gunshot fired by the individual to which the gunshot detection device is attached. If the acceleration data corresponds to a gunshot fired by the individual to which the gunshot detection device is attached, then the wearable gunshot detection device transmits the acceleration data to the remote monitoring system. | 11-26-2015 |
20150335644 | COMPOSITIONS AND METHODS FOR TREATING SKIN CANCER ASSOCIATED DISEASES - The invention provides compositions and methods for treating skin cancer associated diseases. Specifically, the invention relates to topically administering a signaling pathway inhibitor or a related compound to treat pre-cancerous skin lesions, skin tumors, and their associated diseases or disorders. | 11-26-2015 |
20150327783 | NONINVASIVE 4-D TIME-RESOLVED DYNAMIC MAGNETIC RESONANCE ANGIOGRAPHY - A method for non-contrast enhanced 4D time resolved dynamic magnetic resonance angiography using arterial spin labeling of blood water as an endogenous tracer and a multiphase balanced steady state free precession readout is presented. Imaging can be accelerated with dynamic golden angle radial acquisitions and k-space weighted imaging contrast (KWIC) image reconstruction and it can be used with parallel imaging techniques. Quantitative tracer kinetic models can be formed allowing cerebral blood volume, cerebral blood flow and mean transit time to be estimated. Vascular compliance can also be assessed using 4D dMRA by synchronizing dMRA acquisitions with the systolic and diastolic phases of the cardiac cycle. | 11-19-2015 |
20150322169 | Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody - The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof. | 11-12-2015 |
20150306284 | IMPLANTABLE MEDICAL DEVICES THAT ARE RESISTANT TO IMMUNE CELL MEDIATED SURFACE DAMAGE - Methods for protecting biomaterials comprise attaching CD47 or Ig domain thereof to the surface of the biomaterial, thereby inhibiting or reducing immune cell attachment and/or immune cell-mediated damage to the biomaterial. Also provided are kits for practicing these methods and the protected biomaterials. | 10-29-2015 |
20150250786 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF - The present invention relates to pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of depression and/or anxiety. | 09-10-2015 |
20150209407 | METHODS FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS AND BONE-RELATED DISEASES - The present disclosure is directed to the identification that R-Spondin-1 (RSpo1) acts as a positive regulator of bone formation. Accordingly, the presently disclosed subject matter provides methods for treating and/or preventing osteoporosis or bone-related disorders, including administering a pharmaceutical composition of a therapeutically effective amount of an R-Spondin (RSpo) agonist, e.g., an RSpo protein or functional fragment thereof, peptidomimetic, nucleic acid, small molecule, or other drug candidate, to a subject, e.g., a mammal. In one exemplary embodiment, the RSpo agonist is a therapeutic vector including a nucleic acid molecule encoding RSpo protein or a functional fragment thereof. The presently disclosed subject matter also provides methods for diagnosing osteoporosis and other bone-related disorders using RSpo as a marker, as well as screening methods for identifying other proteins that are involved in bone formation. | 07-30-2015 |
20150203539 | MODIFIED COMPSTATIN WITH PEPTIDE BACKBONE AND C-TERMINAL MODIFICATIONS - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13. | 07-23-2015 |
20150197740 | FUNCTION AND REGULATION OF ADAMTS-1 - The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1. | 07-16-2015 |
20150196628 | COMBINATION IMMUNO THERAPY AND RADIOTHERAPY FOR THE TREATMENT OF HER-2-POSITIVE CANCERS - This invention provides methods for inducing an immune response against a Her-2/neu antigen-expressing tumor and for treating the same and vaccinating against the same in human and canine subjects using a combination of radiation therapy and a recombinant attenuated | 07-16-2015 |
20150191724 | U1 snRNP Regulates Gene Expression and Modulates Oncogenicity - The present invention relates to the discovery of a novel global gene expression regulation mechanism whereby U1 snRNP (U1) protects pre-mRNAs. In one embodiment, the invention includes compositions and methods for regulating gene expression and treating diseases associated with dysregulated gene expression. | 07-09-2015 |
20150190477 | IGF-1 PROTEINS AND THERAPEUTIC USES THEREOF - The present disclosure provides for techniques using pro-IGF-I for increasing IGF-I activity. Accordingly, the present disclosure provides for compositions and methods for treating or preventing a disease or disorder mediated by IGF-I. In addition, the present disclosure provides for kits for use in the treatment or prevention of a disease or disorder mediated by IGF-I. | 07-09-2015 |
20150190428 | Methods for Assessing the Suitability of Transduced T Cells for Administration - The invention relates to of analyzing vector supernatants useful for transducing T cells destined for administration to a human subject. The invention also related to methods of analyzing transduced T cells destined for administration to a human subject. | 07-09-2015 |
20150159173 | METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR - A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences. | 06-11-2015 |
20150158915 | Compstatin Analogs with Improved Pharmacokinetic Properties - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed. | 06-11-2015 |
20150158913 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY - Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed. | 06-11-2015 |
20150132778 | METHODS AND KITS FOR DIAGNOSING HEPARIN-INDUCED THROMBOCYTOPENIA - Provided herein are methods for diagnosing heparin-induced thrombocytopenia (HIT) in a subject. The methods comprise (a) contacting a PF4-heparin complex with a biological sample from the subject; (b) contacting the composition of part (a) with an HIT-like antibody; and (c) measuring the amount of bound HIT-like antibody. In one embodiment, a significant decrease in the amount of bound HIT-like antibody in the composition of part (b) as compared to a control level is indicative of a diagnosis of HIT in the subject. Also provided are assay kits for performing the methods of the invention. | 05-14-2015 |
20150125507 | BIOMATERIALS FOR ENHANCED IMPLANT-HOST INTEGRATION - The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure is provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization. | 05-07-2015 |
20150119263 | CARBON NANOTUBE BIOSENSORS AND RELATED METHODS - Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease. | 04-30-2015 |
20150105946 | THREE-DIMENSIONAL MANIPULATION OF TEAMS OF QUADROTORS - A system and method is described for controlling flight trajectories of at least two flying vehicles towards goal positions. The system includes at least two flying vehicles with onboard inertial measurement units for determining and updating orientation, angular velocities, position and linear velocities of the at least two flying vehicles, a motion capture system to detect current position and velocity of each of the at least two flying vehicles, and a base controller in communication with the motion capture system and in communication with the plurality of flying vehicles. The base controller calculates for each of the flying vehicles, at predetermined intervals of time, optimum trajectory paths using piece-wise smooth polynomial functions, applying weighting factors, and enforcing overlap constraints. | 04-16-2015 |
20150087004 | Microfabricated 3D Cell Culture System - Device for 3D cell culture using an extracellular matrix including a substrate having at least one interior chamber, at least one opening providing access to the interior chamber for introduction of an extracellular matrix, and at least one channel disposed through at least a portion of the extra cellular matrix. | 03-26-2015 |
20150079024 | METHODS FOR MODULATING AN INFLAMMATORY RESPONSE - The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity. | 03-19-2015 |
20150065363 | BIOMIMETIC CHEMICAL SENSORS USING NANOELECTRONIC READOUT OF OLFACTORY RECEPTORS - The present invention provides biomimetic sensor devices that utilize proteins—such as G-protein coupled receptors—and are useful in high-sensitivity analysis of analyte-containing samples. These sensors may be used to determine the presence or concentration of one or more analytes in a sample. The invention also includes methods of fabricating the devices and methods of using the devices to assay samples. | 03-05-2015 |
20150039734 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR ENABLING REAL-TIME GUARANTEES IN PUBLISH-SUBSCRIBE MIDDLEWARE USING DYNAMICALLY RECONFIGURABLE NETWORKS - The subject matter described herein includes methods, systems, and computer readable media for enabling real-time guarantees in publish-subscribe middleware with dynamically reconfigurable networks. One exemplary method includes providing a publish-subscribe middleware interface usable by publishers and subscribers to request quality of service guarantees for data delivery across a network. The method also includes providing a global resource manager for receiving quality of service requests from the subscribers, for evaluating the requests, and for dynamically reconfiguring network resources to provide the requested quality of service guarantees. | 02-05-2015 |
20150025625 | CARDIAC REPAIR PROSTHESIS SETS AND METHODS - Cardiac repair prostheses, sets, and methods for implanting in an aorta are disclosed. Cardiac repair prosthesis sets can include a radially expandable support supporting a unidirectional valve that is configured for implantation into the aortic valve region of a patient and a second radially expandable support for a substantially blood impervious stent having a size and shape for implantation into the ascending aorta of said patient where the unidirectional valve and stent are configured for integration within the patient by at least one joining element. Cardiac repair prostheses can include a radially expandable support supporting a unidirectional valve configured for implantation into the aortic valve region of a patient and a second radially expandable support for a substantially blood impervious stent having a size and shape for implantation into the ascending aorta of said patient where the unidirectional valve and stent are joined by at least one joining element. | 01-22-2015 |
20150017638 | METHODS FOR ASSESSING RISK FOR CANCER USING BIOMARKERS - The present disclosure is directed to methods and kits for detecting, characterizing, preventing, and treating cancer, e.g., pancreatic cancer, or inflammation, by determining the presence of circulating epithelial in a biological sample and further identifying the tissue of origin using a tissue-specific biomarker, e.g., Pdx-1. | 01-15-2015 |
20150017141 | USE OF ICOS-BASED CARS TO ENHANCE ANTITUMOR ACTIVITY AND CAR PERSISTENCE - The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain. | 01-15-2015 |
20150010551 | Compositions and Methods of Treating Tumors - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 01-08-2015 |
20140377224 | Method of Treating or Retarding the Development of Blindness - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method. | 12-25-2014 |
20140371261 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER - Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects. | 12-18-2014 |
20140357505 | System And Method Of Cytomic Vascular Health Profiling - The present invention relates to a method of determining vascular health in a subject. The method includes the steps of obtaining a biological sample from the subject, obtaining microparticle data based on the level of at least one set of microparticles in the biological sample, obtaining progenitor cell data based on the level of at least one set of progenitor cells in the biological sample, generating a cytometric fingerprint of the biological sample based on the microparticle and progenitor cell data, and determining the vascular health of the subject based on the generated cytometric fingerprint. | 12-04-2014 |
20140356287 | PLOD2 as a Target of Intervention for Sarcoma Metastasis - The invention provides compositions and methods for treating a disease or disorder by lowering the level of PLOD2 in a subject. | 12-04-2014 |
20140348790 | ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME - The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors. | 11-27-2014 |
20140343114 | Potent poxvirus inhibitor - This invention provides compounds of formulas (I), (II), (III), and (IV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a poxvirus infection in a subject using the compounds or compositions. | 11-20-2014 |
20140343080 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF - The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention. | 11-20-2014 |
20140341941 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 11-20-2014 |
20140335111 | VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING THE SAME - Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed. | 11-13-2014 |
20140329234 | FLUORESCENT LABELING OF TRANSFER RNA AND STUDY OF PROTEIN SYNTHESIS - Provided are methods for labeling transfer RNA comprising replacing the uracil component of a dihydrouridine of said transfer RNA with a fluorophore. The disclosed methods may comprise fluorescent labeling of natural tRNAs (i.e., tRNAs that have been synthesized in a cell, for example, in a bacterium, a yeast cell, or a vertebrate cell) at dihydrouridine (D) positions, or fluorescent labeling of synthetic tRNAs. In another aspect, the present invention provides methods for assessing protein synthesis in a translation system comprise providing a tRNA having a fluorophore substitution for the uracil component of a dihydrouridine in a D loop of the tRNA; introducing the labeled tRNA into the translation system; irradiating the translation system with electromagnetic radiation, thereby generating a fluorescence signal from the fluorophore; detecting the fluorescence signal; and, correlating the fluorescence signal to one or more characteristics of the protein synthesis in the translation system. The disclosed methods are useful in single molecule as well as in ensemble settings. | 11-06-2014 |
20140322216 | GLYPICAN-3-SPECIFIC ANTIBODY AND USES THEREOF - The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. | 10-30-2014 |
20140317389 | COMPUTATIONAL SPRINTING USING MULTIPLE CORES - A multi-core processing system that uses computational sprinting to generate high levels of computational output for short periods of time at power consumption levels that are not sustainable over longer periods of time due to thermal and/or other constraints. This is done using a number of processing cores that, when operated simultaneously, utilize available thermal capacity within the system to consume power and produce heat that is in excess of a thermal design power (TDP) of the system, but is tolerable because of the short period of operation. The system and/or method described herein may include thermal capacitors in the form of phase change materials (PCMs), may implement normal, sprint and/or cooling modes of operation, and may employ parallel sprinting, frequency sprinting, sprint pacing and/or sprint-and-rest techniques, to cite several possibilities. | 10-23-2014 |
20140314855 | COATED MESOPOROUS NANOPARTICLES - Provided are methods for producing mesoporous nanoparticles that can, once loaded, retain small or large molecules (e.g., molecules having a molecular weight that is less or greater than about 900 Da) until release is desired, upon which time the mesoporous nanoparticles can release the loaded molecule in a controlled manner for a desired period of time, including an extended period of time. Also disclosed are methods for treating a subject comprising administering to the subject a mesoporous nanoparticle according to the present disclosure. | 10-23-2014 |
20140309246 | METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES - This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for inhibiting cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, and methods for treating these disorders. | 10-16-2014 |
20140309169 | Methods and Compositions for Inhibiting Delayed Graft Function - Disclosed are compositions and methods for inhibiting preventing, reducing delayed graft function, allograft rejection or ischemia reperfusion injury. | 10-16-2014 |
20140308682 | GRAPHENE-BIOMOLECULE BIOELECTRONIC DEVICES - Provided are devices and methods featuring a nanoelectronic interface between graphene devices (for example, field effect transistors or FETs) and biomolecules such as proteins, which in turn provides a pathway for production of bioelectronic devices that combine functionalities of the biomolecular and inorganic components. In one exemplary application, one may functionalize graphene FETs with fluorescent proteins to yield hybrids that respond to light at wavelengths defined by the optical absorption spectrum of the protein. The devices may also include graphene in electronic communication with a biomolecule that preferentially binds to a particular analyte. | 10-16-2014 |
20140308379 | USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISORDERS AND VIRAL DISEASES - The invention provides compositions and methods for treating neurological disorders and viral infection using whole-grain flaxseed, flaxseed lignans such as Secoisolariciresinol diglucoside (SDG), human lignans metabolized from flaxseed such as Enterodiol (ED) or Enterolactone (EL), and synthetic flaxseed lignan analogs. | 10-16-2014 |
20140303209 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side-Effects - The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds. | 10-09-2014 |
20140295426 | Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids - A method for diagnosing or differentially diagnosing a cancer characterized by the presence of cancer cells in the pleural fluid of a mammalian subject, the method comprising contacting a sample of pleural fluid of the subject with colloidal magnetic particles coupled to a ligand which binds to a determinant on a cancer cell, but does not bind above a baseline threshold to other cellular and non-cellular components in pleural fluid; subjecting the pleural fluid-magnetic particle mixture to a magnetic field to produce a cell fraction enriched in ligand coupled-magnetic particle-bound cancer cells, if present in the pleural fluid; and analyzing the enriched fraction for the number of cancer cells in the pleural fluid. In certain aspects, this method involves preparing the pleural fluids for the above-noted method steps by, e.g., dilution of unprocessed pleural fluid. In certain aspect, the pleural fluid is subjected to the diagnostic method within 24 hours of withdrawal from the subject. This method has advantages to present diagnostic procedures for identifying malignant pleural effusions. The tumor cells present in pleural fluid can be characterized with cellular and molecular markers to determine prognostic and predictive factors. | 10-02-2014 |
20140294861 | ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to B7-H4-specific compositions and methods of use thereof. | 10-02-2014 |
20140294846 | FUNCTION AND REGULATION OF ADAMTS-1 - The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1. | 10-02-2014 |
20140288353 | VENTRICULAR ASSIST DEVICE SLEEVE ADAPTER - A sleeve adapter for connecting a ventricular assist device to a ventricle of the heart. | 09-25-2014 |
20140286973 | CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR FOLATE RECEPTOR BETA - The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML). The invention also relates to at least one chimeric antigen receptor (CAR) specific to folate receptor beta (FRβ), vectors comprising the same, and recombinant T cells comprising the FRβ CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a FRβ binding domain in combination with a RXR agonist, such as all-trans retinoic acid. | 09-25-2014 |
20140271864 | THERAPEUTIC COMPOSITIONS FOR BONE REPAIR - Individuals having diabetes are more prone to fractures, periodontitis, and other bone related issues as compared to healthy individuals. Furthermore, bone healing in diabetic patients is prolonged. The invention provides a method for decreasing bone resorption or increasing bone formation or promoting bone healing in diabetic patients. In particular, a biodegradeable polymer, such as a polyanhydride salicylate is administered at or near a bone defect site, and upon hydrolysis of the polymer will releases biologically active salicylic acid. | 09-18-2014 |
20140271635 | TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR - The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain. | 09-18-2014 |
20140271550 | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses - A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated. | 09-18-2014 |
20140256803 | TUMOR NECROSIS FACTOR INHIBITORS - The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions. | 09-11-2014 |
20140249184 | POLYMER-BASED SURGICALLY IMPLATABLE HALOPERIDOL DELIVERY SYSTEMS AND METHODS FOR THEIR PRODUCTION AND USE - Surgically implantable drug delivery systems for long-term delivery of haloperidol containing a biodegradable polymer and haloperidol fabricated into the surgically implantable drug delivery systems via solvent casting and compression molding are provided. Also provided are methods for producing the surgically implantable drug delivery systems and methods for using these systems in the treatment of psychotic disorders such as schizophrenia. | 09-04-2014 |
20140248304 | NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME - The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest. | 09-04-2014 |
20140242111 | Engineered Bacteria for Oral Delivery of Glucoregulatory Proteins - Disclosed is an oral delivery system that overcomes major barriers encountered in the gastrointestinal tract, particularly rapid proteolytic degradation and low intestinal permeability. Provided is a method for oral delivery of an engineered microorganism to a mammal where the microorganism produces a macromolecule having a desired bioavailability outcome. | 08-28-2014 |
20140234348 | Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens - The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain. | 08-21-2014 |
20140234321 | HUNK, A SNF1-RELATED KINASE ESSENTIAL FOR MAMMARY TUMOR METASTASIS - This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the role of HUNK in tumor metastasis, primary tumor development, and the prediction of tumor behavior. | 08-21-2014 |
20140234221 | ANTIGEN-BINDING PROTEINS COMPRISING RECOMBINANT PROTEIN SCAFFOLDS - Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use. | 08-21-2014 |
20140221451 | IMPLANTS FOR THE TREATMENT OF DOPAMINE ASSOCIATED STATES - Biodegradable implants comprising dopamine modulating compounds are described. | 08-07-2014 |
20140220555 | IN VITRO MICROPHYSIOLOGICAL SYSTEM FOR HIGH THROUGHPUT 3D TISSUE ORGANIZATION AND BIOLOGICAL FUNCTION - Techniques for generating microtissues, including a micro-fabricated platform including at least one micro-well including a plurality of micro-cantilevers coupled thereto and surrounded by a plurality of ridges, each micro-cantilever including a cap at a terminal end thereof. The platform can be immersed in a suspension of cells. The suspension of cells can be driven into at least one micro-well, and the ridges can be de-wetted to remove excess suspension and isolate the suspension of cells in each micro-well. The cells can be driven in the suspension of each micro-well toward a top surface of the suspension, which can be polymerized to form a matrix. The cells can be cultivated to spontaneously compact the matrix such that the micro-cantilevers anchor and constrain the contracting matrix to form a band of microtissue that spans across the micro-cantilevers. | 08-07-2014 |
20140219999 | TREATMENT OF COLON CANCER USING COMPLEMENT INHIBITORS - Methods for treating, preventing or delaying onset of polyp formation and subsequent colon cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumorigenic or pre-tumorigenic tissue. | 08-07-2014 |
20140213887 | CEST MRI METHODS FOR IMAGING GLUTAMINOLYSIS IN CANCER - CEST imaging technique and MR scanning are used as an MRI method for measuring glutaminase mediated tumors. The method takes advantage of the fact that glutamine does not exhibit a significant Chemical Exchange Saturation Transfer (CEST) effect while glutamate does. In accordance with this method, one first obtains a glutamate CEST MRI map of the area of a tumor. L-glutamine (nontoxic up to several millimolar level) or glutaminase blocker is then injected and a post injection Glutamate CEST map is obtained. The difference in the spatial maps indicates the level of expression of glutaminase in the tumor. | 07-31-2014 |
20140212446 | Novel Artificial Antigen Presenting Cells and Uses Thereof - The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit. | 07-31-2014 |
20140212427 | Anti-Properdin Antibodies and Uses Thereof - This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-properdin antibody. Specifically, the invention relates to methods of treating an AP-mediated pathology or AP-mediated condition in an individual by contacting the individual with an anti-properdin antibody. | 07-31-2014 |
20140210467 | MAGNETIC RESONANCE IMAGING APPARATUS AND SUSCEPTIBILITY-WEIGHTED IMAGING METHOD USING THE SAME - An MRI system acquires a susceptibility-weighted image by acquiring a first RF echo signal in a first echo time for providing an image exclusive of susceptibility-weighting and acquiring a second RF echo signal in a second echo time longer than the first echo time for providing an image including susceptibility-weighting. A compensation gradient field is applied for compensating for field inhomogeneity and in response, a third RF echo signal is acquired in a third echo time longer than the second echo time. First, second and third images are generated in response to data derived from the first, second and third RF echo signals respectively and data of the first, second and third images is combined to provide image data representing an image compensating for magnetic resonance signal attenuation in the second image. | 07-31-2014 |
20140206059 | Transcriptome Transfer Produces Cellular Phenotype Conversion - The present invention includes methods for effecting phenotype conversion in a cell by transfecting the cell with phenotype-converting nucleic acid. Expression of the nucleic acids results in a phenotype conversion in the transfected cell. Preferably the phenotype-converting nucleic acid is a transcriptome, and more preferably an mRNA transcriptome. | 07-24-2014 |
20140193811 | Culture Based Screening Assay and Methods of Use Thereof to Identify Agents Which Modulate Tumor Development, Invasion and Differentiation - A 3D organotypic culture which phenocopies aggressive, invasive cancer and methods of use thereof are provided. | 07-10-2014 |
20140187579 | TIP60 INHIBITORS - This invention is in the fields of immunology and autoimmunity. More particularly it concerns pharmaceutical compositions comprising compounds which are useful agents for inhibiting the functions of TIP60 and the use of such compounds in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases. | 07-03-2014 |
20140186947 | Activation and Expansion of T-Cells Using an Engineered Multivalent Signaling Platform as a Research Tool - Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon. | 07-03-2014 |
20140186384 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 07-03-2014 |
20140180167 | SYSTEM AND METHOD FOR DETERMINING STRICTURE CHARACTERISTICS - Systems and methods for determining stricture characteristics are disclosed. A system for determining the characteristics of a stricture in a body lumen includes a dilation device, one or more sensors, and an output device. The dilation device is configured to be inserted in the body lumen at the location of the stricture. The one or more sensors are coupled to the dilation device for sensing characteristics of the dilation device during dilation. The output device is configured to indicate the characteristics of the dilation device. In order to determining the characteristics of the stricture, the dilation device may be inserted in the body lumen at the location of the stricture. The dilation device may then be inflated. Characteristics of the dilation device during inflation of the dilation device may then be sensed. | 06-26-2014 |
20140170114 | GLYPICAN-3-SPECIFIC ANTIBODY AND USES THEREOF - The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. | 06-19-2014 |
20140163390 | Implantable Biomedical Devices on Bioresorbable Substrates - Provided herein are implantable biomedical devices and methods of administering implantable biomedical devices, making implantable biomedical devices, and using implantable biomedical devices to actuate a target tissue or sense a parameter associated with the target tissue in a biological environment. | 06-12-2014 |
20140155476 | SIMIAN SUBFAMILY E ADENOVIRUSES SAdV-39, -25.2, -26, -30, -37, AND -38 AND USES THEREOF - A recombinant vector comprises simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -38 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-39, -25.2, -26, -30, -37, and -383 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 06-05-2014 |
20140147631 | MANUFACTURE OF HYDROPHOBIC SURFACES - Provided are methods of producing hydrophobic surfaces that in some embodiments include nanoparticle populations that differ in cross-sectional dimension and a coating of a low surface energy material. Also are provided are methods for producing such hydrophobic surfaces. Methods for producing transparent hydrophobic surfaces with functionalized nanoparticles and low surface energy polymers are also provided. | 05-29-2014 |
20140144506 | GRATING STRUCTURE FOR DIVIDING LIGHT - A grating structure and a solar cell assembly. In one aspect, the grating structure suppresses the zero order transmission to near 0%. In another aspect, the solar cell assembly has improved absorption due to coupling with a grating structure. | 05-29-2014 |
20140140926 | Novel Peptides and Methods Using Same - The present invention includes a method of modulating the phagocytic activity of at least one phagocyte in a subject. The present invention also includes a method of providing a composition resistant to phagocytosis to a subject. The present invention further includes a method of treating, ameliorating or preventing an inflammatory disease in a subject. | 05-22-2014 |
20140135298 | MUTATION MIMICKING COMPOUNDS THAT BIND TO THE KINASE DOMAIN OF EGFR - This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for treating cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, particularly for expanding the efficacy of drugs previously developed for this purpose, and for methods of treatments using the compounds for this purpose. | 05-15-2014 |
20140113874 | Modified Compstatin With Improved Stability And Binding Properties - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These cyclic compounds are modified to improve stability while maintaining substantially equivalent complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs in which the disulfide bond between C2 and C12 is modified via a thioether bond to form a cystathionine. | 04-24-2014 |
20140107530 | System and Method for Diagnosing Onset of Osteoarthritis - The present invention relates to a method of diagnosing/predicting a degenerative disease in the hip of a subject. The method including the steps of applying a compressive force on at least one hip joint of the subject and calculating a compression index value for at least one hip joint, wherein a non-zero compression index value for the at least one hip joint is indicative of the subject developing/having a degenerative disease. The present invention also relates to a diagnostic test for determining incongruity in a hip joint of a subject, where the test includes the steps of applying a compressive force on at least one hip joint of the subject and calculating a compression index value, wherein a non-zero compression index value for the hip joint is indicative of at least mild hip joint incongruity. | 04-17-2014 |
20140107085 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof - The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention. | 04-17-2014 |
20140106449 | Use of Chimeric Antigen Receptor-Modified T Cells to Treat Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 04-17-2014 |
20140106351 | METHODS AND SYSTEMS FOR IDENTIFYING MICRO-RNA TARGETS AND SYNTHESIZING NOVEL MICRO-RNAS AND USES OF THE SAME - Method of identifying a microRNA-recognition element and of generating microRNAs are disclosed. System and computer programs for performing such methods are disclosed. Recombinant nucleic acid molecule comprising a heterologous coding sequences and one or more MREs are also disclosed as are isolated nucleic acid molecule comprising one or more MRE sequences and being free of a coding sequence operably linked to regulatory elements. MicroRNA generated by a methods of the invention and the use of the microRNAs to downregulate gene expression are disclosed. | 04-17-2014 |
20140106260 | CORE-SHELL NANOPARTICULATE COMPOSITIONS AND METHODS - Core-shell nanoparticulate compositions and methods for making the same are disclosed. In some embodiments core-shell nanoparticulate compositions comprise transition metal core encapsulated by metal oxide shell. Methods of catalysis comprising core-shell nanoparticulate compositions of the invention are disclosed. Compositions comprising core-shell nanoparticles displayed on a metal-oxide support and methods for preparing the same are also disclosed. In some embodiments compositions comprise core-shell nanoparticles displayed as a substantially single layer superposed on a metal oxide support. Methods of catalysis employing the supported core-shell nanoparticles are disclosed. | 04-17-2014 |
20140105818 | Novel Vesicles and Nanostructures from Recombinant Proteins - The present invention includes a composition comprising at least one oleosin-like protein. The present invention also includes a composition comprising a vesicle comprising at least one oleosin-like protein. | 04-17-2014 |
20140099340 | Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain. | 04-10-2014 |
20140099309 | Use of a Trans-Signaling Approach in Chimeric Antigen Receptors - The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation. | 04-10-2014 |
20140088992 | METHOD AND SYSTEM FOR DETECTING AND CATEGORIZING DISEASE - The presently disclosed subject matter relates to the diagnosis of diseases, and more particularly to the diagnosis of diseases using information contained within an electronic medical record. In particular, the presently disclosed subject matter provides for systems and methods for monitoring, detecting and categorizing disease states. In one embodiment, the system and method can include determining the present or indication of one or more disease state criteria and alerting the hospital information system and at least one clinician if at least one or more disease state criteria are present or indicated. | 03-27-2014 |
20140088207 | POLYMERIZED IONIC LIQUID BLOCK COPOLYMERS AS BATTERY MEMBRANES - The present invention is directed to compositions useful for use in separators for use in lithium ion batteries, and membranes, separators, and devices derived therefrom. | 03-27-2014 |
20140087005 | MODULATORS OF HSP70/DNAK FUNCTION AND METHODS OF USE THEREOF - Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed. | 03-27-2014 |
20140066486 | REL INHIBITORS AND METHODS OF USE THEREOF - This invention provides REL inhibitors which interfere with the DNA binding capacity of a REL protein. Additionally this invention provides methods of treating, abrogating, or preventing diseases which respond with a positive clinical score to a REL inhibitor. Methods of identifying REL inhibitor based on a REL protein three dimensional model are described. | 03-06-2014 |
20140065105 | Simian Adenovirus Nucleic Acid and Amino Acid Sequences, Vectors Containing Same, and Methods of Use - A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 03-06-2014 |
20140051923 | PED-Endoscope Image and Diagnosis Capture System - A personal electronic device (PED)-endoscope image and diagnosis capture system is provided. The system includes a PED adapter having a magnification lens connection side and a PED connection side. A magnification lens is connectable with the lens connection side of the PED adapter. An eyepiece lens coupler is also provided and connects the magnification lens to the endoscope eyepiece. A PED is connected to the PED adapter and includes a processor, a memory and an image capture system with a PED lens. The PED adapter aligns the magnification lens with the PED lens. The processor is configured to activate the image capture system using a remote or voice-activated trigger signal and store captured images in the PED memory. Patient data and examination data can be associated with the images, and the images and data can be transferred from the PED to an electronic medical records system. | 02-20-2014 |
20140044680 | Simian Subfamily B Adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and Uses Thereof - A recombinant vector comprises simian adenovirus 28, simian adenovirus 27, simian adenovirus 32, simian adenovirus 33, and/or simian adenovirus 35 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-28, -27, -32, -33, or -35 genes is also disclosed. Methods of using the vectors and cell lines are provided. | 02-13-2014 |
20140037599 | Compositions and Methods of Treating T Cell Deficiency - The invention provides compositions and methods for genetically modifying T cell progenitor cells (TCPC) to express TCF-1 to differentiate the TCPC, or its progeny, into a T cell. The invention also provides methods of using a T cell derived from a TCPC to treat a subject having a disease or disorder involving T cell deficiency. | 02-06-2014 |
20140031418 | Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens - A prophylactic regimen for passively preventing infection with a pathogen which has a typical route of infection through the nasopharynx region of a subject, e.g., an airborne virus typically transmitted through coughing or sneezing. The method involves specifically targeting a subject's nasopharynx with a viral vector comprising an AAV capsid and carrying a nucleic acid sequence encoding an anti-viral neutralizing antibody construct operably linked to expression control sequences, in order to provide for high levels of expression of the anti-viral neutralizing antibody construct in the nasal airway cells. Optionally, the neutralizing antibody construct is expressed under a promoter which is regulated or induced by a small molecule which is delivered separately from the viral vector. In one embodiment, the method permits transfection of a subject's nasopharynx even where the subject has circulating neutralizing antibodies against the AAV capsid. | 01-30-2014 |
20140031410 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOGENESIS - The invention generally features compositions and methods that are useful for modulating angiogenesis. | 01-30-2014 |
20140030267 | COMPOSITIONS, METHODS AND KITS RELATING TO RESISTIN - The invention relates to novel nucleic acids encoding a mammalian resistin gene, and proteins encoded thereby, whose expression is suppressed by the antidiabetic compounds thiazolidinediones. The invention further relates to methods of treating and detecting type 2 diabetes and Syndrome X comprising modulating or detecting resistin expression and/or production and activity of resistin polypeptide. | 01-30-2014 |
20140024635 | INHIBITORS OF THE INFLUENZA A VIRUS M2 PROTON CHANNEL - Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. | 01-23-2014 |
20140024032 | Method for Detecting Chromosome Structure and Gene Expression Simultaneously in Single Cells - The present invention relates to systems and methods for measuring chromosome structure and gene expression. In one embodiment, the present invention includes an assay for determining the spatial organization of gene expression in the nucleus. The present invention also includes a method based on fluorescence in situ hybridization (FISH) that simultaneously yields information on the physical position and expression of individual genes. By lighting up a large number of targets on a particular chromosome using a bar-coding scheme, the large scale structure of an entire chromosome can be determined. | 01-23-2014 |
20140023613 | Nucleic Acid Molecule Encoding Hepatitis B Virus Core Protein And Vaccine Comprising The Same - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequence of HBV core protein, as well as genetic constructs/vectors and vaccines that express said protein sequences. Also provided herein are methods for generating an immune response against HBV using the nucleic acid sequences that are provided. | 01-23-2014 |
20140005147 | DNA POLYMERASE INHIBITORS COMPOSITION AND METHODS | 01-02-2014 |
20140004143 | ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR | 01-02-2014 |
20130338117 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES - This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided. | 12-19-2013 |
20130338080 | COMPOSITIONS AND METHODS FOR TREATING AN ACTIVATED B-CELL DIFFUSE LARGE B-CELL LYMPHOMA - The invention relates to compositions and methods for treating an activated B-Cell Diffuse Large B-Cell Lymphoma (ABC-DLBCL). Specifically, the invention relates to treating ABC-DLBCL by administering an NF-κB Essential Modulator (NEMO) Binding Domain (NBD) peptide or a mimetic thereof that inhibits NF-κB activation. | 12-19-2013 |
20130337463 | Cell-Based Models of Neurodegenerative Disease - The present invention relates to a cell-based model useful for identifying molecules that modify intracellular pathways of α-synuclein and tau aggregation and degradation. | 12-19-2013 |
20130333080 | Prunus plant named 'Chestnut Hill' - A new and distinct | 12-12-2013 |
20130331329 | BIOMARKERS FOR SEIZURES - The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits. | 12-12-2013 |
20130330835 | DEVICES AND METHODS FOR GRAVIMETRIC SENSING IN LIQUID ENVIRONMENTS - Devices and methods for gravimetric sensing are disclosed. A gravimetric sensor includes a piezoelectric resonator and an encapsulating layer formed on the surface of the resonator. The encapsulating layer defines a channel within the encapsulating layer on the surface of the resonator. The sensor is fabricated by forming a piezoelectric resonator, forming a sacrificial layer on a surface of the piezoelectric resonator, forming an encapsulating layer over the sacrificial layer on the resonator, and etching the sacrificial layer to remove the sacrificial layer and form a channel on the surface of the resonator. The sensor is used by supplying the liquid to the channel of the gravimetric sensor, operating the piezoelectric resonator, detecting a change in a resonant frequency of the resonator, and determining a presence of the analyte in the liquid from the change in resonant frequency of the resonator. | 12-12-2013 |
20130326646 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING NEUROLOGICAL CONDITIONS - The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins. | 12-05-2013 |
20130323283 | COMPOSITIONS AND METHODS FOR TREATING FOXP3+ TREG RELATED DISEASES - Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease comprise (a) contacting a candidate agent with a test sample comprising Foxp3+ T regulatory cells (Tregs), and (b) comparing a function of the Foxp3+ Tregs in the test sample with that in a control sample, wherein inhibition of the function of the Foxp3+ Tregs in the test sample when compared with the control sample indicates that the candidate agent is an agent useful for treating or preventing a Foxp3+ Treg related disease. | 12-05-2013 |
20130323226 | Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer - A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and a penultimate β-galactose residue. The modification may involve retargeting the vector by temporarily functionally ablate AAV9 binding in a subset of cells, thereby redirecting the vector to another subset of cells. Alternatively, the modification may involve increasing cellular update efficiency by treating the cells with a neuraminidase to expose cell surface β-galactose. Also provided are compositions containing the AAV9 vector and a neuraminidase. Also provided is a method for purifying AAV9 using β-galactose linked to solid support. Also provided are mutant vectors which have been modified to alter their targeting specificity, including mutant AAV9 in which the galactose binding domain is mutated and AAV in which an AAV9 galactose binding domain is engineered. | 12-05-2013 |
20130315871 | SUBFAMILY E SIMIAN ADENOVIRUSES A1302, A1320, A1331 AND A1337 AND USES THEREOF - Recombinant vectors comprise simian adenovirus A1302 (SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1302, SAdV-A1320, SAdV-A1331, and/or SAdV-A1337 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 11-28-2013 |
20130309776 | Graphene-Based Nanopore and Nanostructure Devices and Methods for Macromolecular Analysis - Provided are graphene-based nanopore and nanostructure devices, which devices may include an insulating layer disposed atop the graphene, which can be in a planar shape or nanostructured into a ribbon or other shapes, containing a single graphene layer or several layers. Graphene layers and nanostructures can be placed nearby horizontally or stacked vertically. Also provided are related methods of fabricating and processing such devices and also methods of using such devices in macromolecular analysis. | 11-21-2013 |
20130309258 | Methods for Treatment of Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 11-21-2013 |
20130309205 | Simian Adenoviruses SAdV-36, -42.1, -42.2, and -44 and Uses Thereof - A recombinant vector comprises simian adenovirus 36, simian adenovirus 42.1, simian adenovirus 42.2 and/or simian adenovirus 44 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-36, -42.1, -42.2 or -44 gene(s) is also described. Methods of using the vectors and cell lines are provided. | 11-21-2013 |
20130302358 | MORPHOLOGICALLY AND SIZE UNIFORM MONODISPERSE PARTICLES AND THEIR SHAPE-DIRECTED SELF-ASSEMBLY - Monodisperse particles having: a single pure crystalline phase of a rare earth-containing lattice, a uniform three-dimensional size, and a uniform polyhedral morphology are disclosed. Due to their uniform size and shape, the monodisperse particles self assemble into superlattices. The particles may be luminescent particles such as down-converting phosphor particles and up-converting phosphors. The monodisperse particles of the invention have a rare earth-containing lattice which in one embodiment may be an yttrium-containing lattice or in another may be a lanthanide-containing lattice. The monodisperse particles may have different optical properties based on their composition, their size, and/or their morphology (or shape). Also disclosed is a combination of at least two types of monodisperse particles, where each type is a plurality of monodisperse particles having a single pure crystalline phase of a rare earth-containing lattice, a uniform three-dimensional size, and a uniform polyhedral morphology; and where the types of monodisperse particles differ from one another by composition, by size, or by morphology. In a preferred embodiment, the types of monodisperse particles have the same composition but different morphologies. Methods of making and methods of using the monodisperse particles are disclosed. | 11-14-2013 |
20130287748 | Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 10-31-2013 |
20130271838 | OPTICAL DEVICE USING DOUBLE-GROOVE GRATING - Optical devices using double-groove diffraction gratings having periodic sets of TiO | 10-17-2013 |
20130267678 | TRANSCRIPTOME IN VIVO ANALYSIS - Provided are compositions and methods that permit a hybrid nucleic acid-peptide molecule to enter a cell and when specifically activated within the cell, the molecule anneals to endogenous cellular RNA and permits the isolation of the RNA. | 10-10-2013 |
20130261172 | RNA Containing Modified Nucleosides and Methods of Use Thereof - This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules. | 10-03-2013 |
20130251731 | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies - The present invention relates to biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders. | 09-26-2013 |
20130245216 | SET-LRP POLYMERIZATION OF ACRYLATES IN THE PRESENCE OF ACIDS - SET-LRP polymerization of acrylic monomers under acidic conditions is described. The source of the acidity may be the solvent (e.g., an acetic acid-containing solvent) or in the monomer content (e.g., acrylic acid or methacrylic acid, optionally in combination with other monomers such as methyl methacrylate). | 09-19-2013 |
20130243697 | Novel Chimeric Proteins and Methods for Using The Same - Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell. | 09-19-2013 |
20130238041 | Device and Method Using Integrated Neuronal Cells and an Electronic Device - The present invention provides a device of integrated neuronal cells interfaced with an electronic device and a method of producing the same. | 09-12-2013 |
20130237442 | Methods and Compositions for Diagnosis of Non-Viable Early Pregnancy - Methods and compositions are provided for diagnosing an abnormal early pregnancy in a mammalian subject by contacting a biological sample of the subject with a reagent that enables measurement of certain biomarker targets, e.g., human placental lactogen (hPL) and/or human chorionic gonadotropin (hCG). In one embodiment, the mRNA of these biomarkers is measured in a biological sample, e.g., serum. The absolute levels of mRNA or protein levels, a ratio of mRNA to protein levels, or a pattern of multiple biomarker mRNA and/or protein levels or ratios are measured and a relation to the ratio or pattern of expression levels of the same biomarkers in the same biological fluid of a reference or control female mammalian subject having a normal intrauterine pregnancy (IUP) is determined. The presence of, absence of, or changes in expression levels, ratios or patterns of the biomarker(s) in relation to those of the reference or control correlates with a diagnosis of abnormal pregnancy, i.e., miscarriage or ectopic pregnancy. Various reagents for use in kits and panels for such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these biomarker targets. | 09-12-2013 |
20130217857 | ERBB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 08-22-2013 |
20130217222 | LARGE-SCALE GRAPHENE SHEET: ARTICLES, COMPOSITIONS, METHODS AND DEVICES INCORPORATING SAME - Provided are methods for growing large-size, uniform graphene layers on planarized substrates using Chemical Vapor Deposition (CVD) at atmospheric pressure; graphene produced according to these methods may have a single layer content exceeding 95%. Field effect transistors fabricated by the inventive process have room temperature hole mobilities that are a factor of 2-5 larger than those measured for samples grown on commercially-available copper foil substrates. | 08-22-2013 |
20130217122 | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library - The present invention encompasses a method for expanding an antigen specific T cell from a population of cells. The method of the present invention comprises contacting a population of cells with an MHC restricted antigenic glypican-3 peptide. In some instances, the T cell is expanded using monocyte-derived dendritic cells and defined MHC restricted antigenic glypican-3 peptides. In one embodiment, high-affinity antigen-specific T-cell receptors (TCRs) can be cloned from the antigen specific T cell. | 08-22-2013 |
20130216506 | Bioreactor for Isolation of Rare Cells and Methods of Use - The present invention relates to a bioreactor apparatus, and methods of use, for the isolation of rare blood cells, including hematopoietic stem cells and megakaryocytes. The apparatus includes a soft substrate and an anti-contractility agent, thereby providing a soft microenvironment to cultured cells. The apparatus of the invention is permissive for the survival of non-dividing cells while dividing cells are eliminated. This unique property allows for the simple isolation of rare blood cells without the use of costly equipment and antibodies. | 08-22-2013 |
20130216500 | METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method. | 08-22-2013 |
20130204069 | Compositions and Methods of Treating Tumors - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 08-08-2013 |
20130202866 | MECHANICALLY STABLE NANOPARTICLE THIN FILM COATINGS AND METHODS OF PRODUCING THE SAME - A method for treating a surface comprises depositing a first coating comprising a plurality of nanoparticles on a substrate, wherein the first coating defines a plurality of interstitial spaces; and depositing a second coating comprising metals, metal oxides, or mixtures thereof by atomic layer deposition (ALD) on the first coating and within the interstitial spaces defined by the first coating. A mechanically stable coated product comprises a substrate; a first coating comprising a plurality of nanoparticles deposited on the substrate; wherein the first coating defines a plurality of interstitial spaces; and a second coating comprising metals, metal oxides, or mixtures thereof deposited by atomic layer deposition (ALD) on the first coating and within the interstitial spaces defined by the first coating. The mechanically stable thin film coating imparts mechanical robustness to the nanoparticles thin film, and retains or improves the desired optical and wetting properties of the nanoparticle thin film. | 08-08-2013 |
20130202173 | CLASSIFICATION OF BIOLOGICAL TISSUE BY MULTI-MODE DATA REGISTRATION, SEGMENTATION AND CHARACTERIZATION - A method and apparatus for classifying possibly vulnerable plaques from sets of DCE-MRI images includes receiving a set of MRI slice images obtained at respectively different times, where each slice image includes voxels representative of at least one region of interest (ROI). The images are processed to determine the boundaries of the ROIs and the voxels within the identified boundaries in corresponding regions of the images from each time period are processed to extract kinetic texture features. The kinetic texture features are then used in a classification process which classifies the ROIs as vulnerable or stable. | 08-08-2013 |
20130197068 | RNA Containing Modified Nucleosides and Methods of Use Thereof - This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules. | 08-01-2013 |
20130196346 | METHODS FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES (MDS) - The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS. | 08-01-2013 |
20130195335 | AUTOMATIC QUANTIFICATION OF MITRAL VALVE DYNAMICS WITH REAL-TIME 3D ULTRASOUND - A series of rt-3DE images of the mitral valve are quantitatively analyzed so as to enable, for example, prediction of the degree of recurrent ischemic mitral regurgitation (IMR) and comprehensive assessments of leaflet tethering and “tenting” for the entire mitral valve. In accordance with the method, first, the rt-3DE images are registered with symmetric diffeomorphism to obtain information about how the mitral valve deforms over time. Second, the mitral valve is segmented with the level sets or other known segmentation method at each time point in the cardiac cycle with minimal user interaction. Third, the information about mitral valve structure is reduced into a 3D medial model, a compact representation of shape. In other words, a volumetric segmentation of the mitral valve is condensed to a form that is amenable to clinically relevant morphometry. | 08-01-2013 |
20130190472 | POLYAMIDE COMPOSITES HAVING FLEXIBLE SPACERS - Provided are polyamide nanocomposites incorporating carbon nanotubes and other filler species. Also provided are related methods. | 07-25-2013 |
20130190405 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX - This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor. | 07-25-2013 |
20130190370 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor - The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental. | 07-25-2013 |
20130190254 | POLYPEPTIDES THAT BIND MEMBRANE PROTEINS - Polypeptides which bind to the helical transmembrane region of membrane proteins are disclosed, as are methods for the design of polypeptides that bind to the transmembrane region of membrane proteins. Also provided are methods for the use of the disclosed polypeptides in various applications, as well as products made through the practice of the instant methods. | 07-25-2013 |
20130189698 | In Situ Cloning From Pathological Tissue Specimens - The present invention pertains to methods related to cloning nucleic acids from biological samples, particularly pathological tissue samples. This method includes hybridizing a population of oligonucleotide sequence probes comprising degenerate sequence tags to a fixed tissue, isolating the hybridized oligonucleotide sequence probes and amplifying the sequence tags in the hybridized oligonucleotide sequence probes. This method can be utilized to identify genes associated with disease and to quantitate the expression of disease-related transcripts. The method can also be used to identify truncated mRNAs. | 07-25-2013 |
20130189241 | REGULATED DELIVERY SYSTEMS FOR INNER EAR DRUG APPLICATION AND USES THEREOF - The invention relates to a controlled release delivery compositions and methods of using them for pathologies associated with Otorhinolaryngology and Head and Neck. Specifically, the invention relates to regulating drug delivery by the use of chitosan based matrices together with chitosanases. | 07-25-2013 |
20130186758 | CURRENT-CARRYING NANOWIRE HAVING A NANOPORE FOR HIGH-SENSITIVITY DETECTION AND ANALYSIS OF BIOMOLECULES - Disclosed are devices that feature nanopores formed in graphene sheets, such as graphene ribbons. The graphene sheets include an edge irregularity, such as a zig-zag configuration, a chiral edge, or an armchair-configuration edge, which edges confer on the devices the ability to discriminate between different subunits of a macromolecule translocated through the nanpore. The disclosed devices and methods have application to DNA sequencing and analysis, among other applications. | 07-25-2013 |
20130184441 | Detection of Neurodegenerative Disease - Provided are methods of assessing the absence or presence of a neurodegenerative disease in a subject comprising characterizing TDP-43 in a tissue sample of the subject. Also disclosed are methods for diagnosing a neurodegenerative disease in a subject, and methods for determining the efficacy of a drug against a neurodegenerative disease. Novel antibodies that bind to TDP-43 are also provided. | 07-18-2013 |
20130183343 | System and Method of Preparing and Storing Activated Mature Dendritic Cells - The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like receptor agonists that induce clinically effective immune responses, preferably when used earlier in the disease process. The DCs of the present invention produce desirable levels of cytokines and chemokines, and further have the capacity to induce apoptosis of tumor cells. The cells can be cryopreserved and thawed for later use, thereby reducing the need for repeated pheresis and elutriation processes during vaccine production. These methods can also be utilized to directly target molecules involved in carcinogenetic signaling pathways and cancer stem cells. | 07-18-2013 |
20130178440 | COMPOSITIONS AND METHODS FOR TREATING SKIN CANCER ASSOCIATED DISEASES - The invention provides compositions and methods for treating skin cancer associated diseases. Specifically, the invention relates to topically administering a signaling pathway inhibitor or a related compound to treat pre-cancerous skin lesions, skin tumors, and their associated diseases or disorders. | 07-11-2013 |
20130170057 | TWO MIRROR SYSTEM - A method for producing a multiple surface system that may be a two-mirror surface. The method involves first finding from a given primary curve an appropriate secondary curve. The method then uses ideas from exterior differential systems to grow from the primary curve and the secondary curve, primary and secondary mirror surfaces. The Cartan-Kähler theorem gives a strong indication of the existence of such solution surfaces. | 07-04-2013 |
20130165489 | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof - The present invention includes a method of inhibiting, suppressing or preventing a viral infection in a subject, comprising administering to the subject a pharmaceutical composition comprising one or more of the compounds useful within the invention. | 06-27-2013 |
20130165488 | Novel Thromboxane A2 (TP) Receptor Antagonists - The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention. | 06-27-2013 |
20130164859 | DNA-DECORATED GRAPHENE CHEMICAL SENSORS - The present invention provides a broad response single-stranded DNA-graphene chemical sensor device. The present invention also provides methods for improving the ability of graphene to work as a chemical sensor by using single-stranded DNA as a sensitizing agent. | 06-27-2013 |
20130158058 | HYPERCHOLESTEROLEMIA AND TENDINOUS INJURIES - This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or musculoskeletal soft tissue injury. | 06-20-2013 |
20130157962 | METHODS FOR INHIBITING GROWTH OF PROLACTIN-RESPONSIVE CANCER CELLS WITH CYCLOSPORINE A OR OTHER CYCLOPHILIN INHIBITORS - Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin. | 06-20-2013 |
20130156792 | Uniform field magnetization and targeting of therapeutic formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage. | 06-20-2013 |
20130137774 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX - This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor. | 05-30-2013 |
20130137668 | Antimicrobial Cationic Steroids and Methods of Use - The invention relates generally to antimicrobial cationic steroid pharmaceutical compositions, methods of making antimicrobial cationic steroid pharmaceutical compositions, and methods of using antimicrobial cationic steroid pharmaceutical compositions. | 05-30-2013 |
20130129624 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES - This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits. | 05-23-2013 |
20130123750 | METHODS, COMPOSITIONS AND APPARATUS FOR DELIVERING HETEROLOGOUS MOLECULES TO CELLS - A method for transferring a macromolecular complex to muscle cells by exsanguinating a region of the subject's micro vasculature and delivering the complex to this region under high hydrostatic pressure. A balloon catheter having a balloon that extends substantially the foil length of the cannula that is inserted into the subject is provided for use in the systemic delivery of macromolecular complex. | 05-16-2013 |
20130111615 | RNA Containing Modified Nucleosides and Methods of Use Thereof | 05-02-2013 |
20130101567 | Methods to Expand a T Regulatory Cell Master Cell Bank - Compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells are disclosed. Also provided are uses of the expanded nTregs for cellular therapy. | 04-25-2013 |
20130096942 | Discharge Decision Support System for Post Acute Care Referral - A system and method of recommending post-acute care services to a patient is described. The system and method include the steps of providing a plurality of questions relating to a patient, where each question has at least two selectable answers, and wherein each selectable answer has associated therewith a corresponding score, receiving one of the selectable answers for each of the plurality of questions, calculating a total score corresponding to the sum score of each of the answers selected, and generating a post-acute care referral if the total score meets a predetermined threshold value. | 04-18-2013 |
20130092541 | High-Resolution Analysis Devices and Related Methods - Disclosed are solid-state nanopore devices having pores of nanometer-scale thickness, which ultrathin (e.g., less than 10 nm thick) pores enable devices having improved resolution. Also provided are methods of fabricating such devices and of using such devices. The invention also provides nanometer-thick membranes and related methods of fabricating such membranes, which membranes are useful in high resolution microscopy applications. Further disclosed are devices for detection of analytes—including miRNA—that may be small in size and may also be present in only small quantities. | 04-18-2013 |
20130071409 | ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells - The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents. | 03-21-2013 |
20130065815 | Fn 14/TRAIL Fusion Proteins - Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer. | 03-14-2013 |
20130059289 | ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME - The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors. | 03-07-2013 |
20130058929 | FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION OF THROMBI - Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents. | 03-07-2013 |
20130052222 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 02-28-2013 |
20130045474 | DEVICES AND METHODS FOR DETECTING AND MONITORING HIV AND OTHER INFECTIONS AND DISEASES - Disclosed herein are bio-nanosensor devices and methods suitable for blood assays. The bio-nanosensors are based on thickness shear mode transducer capable of transmitting a shear wave into a biofluid adjacent to a bio-functionalized sensing interface of a piezoelectric crystal. The bio-functionalized sensing interface includes one or more antibodies and/or biomarker-specific ligands capable of sensing HIV. The disclosed bio-nanosensors are capable of defecting the presence of HIV virus at picogram sensitivities using no more than 10 μl of blood in less than 15 minutes. | 02-21-2013 |
20130045186 | Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby - Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided. | 02-21-2013 |
20130041017 | SIRNA-BASED THERAPY OF FIBRODYPLASIA OSSIFICANS PROGRESSIVA (FOP) - This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to compositions and methods for siRNA-based regulation of mutated ACVR1 expression in the treatment of Fibrodysplasia Ossificans Progressiva (FOP). | 02-14-2013 |
20130040309 | Methods and Compositions for In-Vivo Enzyme Capture - The invention includes compositions, methods and kits for the in vivo identification of an enzyme that binds to a substrate. The invention comprises, in part, a photoreactive moiety to aid in identification of such an enzyme. | 02-14-2013 |
20130023569 | Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders - There is provided use of orally available or topically applied deferiprone for prevention of iron-induced eye damage. The use may be for preparation of a medicament or in a method of preventing iron-induced eye damage to an eye of a subject at risk for iron-induced eye damage, the method comprising administering a prophylactically effective amount of deferiprone to the subject. There is also provided the use of deferiprone for treatment of iron-related eye disorders. The use may be for preparation of a medicament or in a method of treatment of damage to an eye of a having eye damage associated with iron, the method comprising topically administering a therapeutically effective amount of deferiprone to the subject. | 01-24-2013 |
20130023561 | Facially Amphiphilic Polymers and Oligomers and Uses Thereof - The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions. The present invention further discloses the design and synthesis of facially amphiphilic polymers and oligomers. | 01-24-2013 |
20130023033 | PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM - The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript. | 01-24-2013 |
20130018454 | Small Diameter Vascular Graft Produced by a Hybrid Method - The present invention relates to a hybrid graft and methods of generating the hybrid graft. The hybrid graft comprises an exterior surface and a luminal surface. The luminal surface comprises a micropattern of grooves to which cells adhere and orient along. The exterior surface comprises electrospun microfibers wherein the microfibers provide mechanical properties to the graft. The hybrid graft is capable supporting endothelial cell attachment, endothelial cell alignment, cell proliferation, and maintaining their in vivo function. The graft of the invention can recapitulate the in vivo morphology and function of natural vascular endothelium. | 01-17-2013 |
20130012860 | METHODS AND COMPOSITIONS TO PREDICT AND DETECT ACUTE REJECTION - In some embodiments, a method to detect acute rejection in allograft from is described. In some embodiments, a method to anticipate an episode of acute rejection in allografts is also described. In some embodiments, a kit for detecting or predicting acute transplant rejection of a transplanted organ is described. | 01-10-2013 |